LONDON, UK / ACCESSWIRE / July 31, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select stocks with the Drug Manufacturers industry and that trades on the Toronto Exchanges. This Morning, our team has regrouped these stocks for study: Valeant Pharmaceuticals International, Knight Therapeutics, and Acerus Pharmaceuticals. Register for these free reports at:

http://protraderdaily.com/register/

On Friday, July 28, 2017, the Toronto Exchange Composite Index was down 0.41%, finishing the day at 15,128.65.

Additionally, the Healthcare index was slightly down by 0.40%, ending the session at 69.02.

Pro-Trader Daily’s complimentary research reports on the following stocks are now available: Valeant Pharmaceuticals International Inc. (TSX: VRX), Knight Therapeutics Inc. (TSX: GUD), and Acerus Pharmaceuticals Corporation (TSX: ASP). Sign up now for your free membership and research reports at:

http://protraderdaily.com/register/

Valeant Pharmaceuticals International, Inc.

Laval, Canada headquartered Valeant Pharmaceuticals International Inc.’s stock declined 2.47%, to finish Friday’s session at $20.96 with a total volume of 1.03 million shares traded. Valeant Pharma’s shares have surged 58.55% in the past three months. Shares of the Company, which operates as a pharmaceutical and medical device company worldwide, are trading above its 50-day and 200-day moving averages. Valeant Pharmaceuticals’ 50-day moving average of $20.66 is above its 200-day moving average of $17.63. See our research report on VRX.TO at:

http://protraderdaily.com/optin/?symbol=VRX

Knight Therapeutics Inc.

On Friday, shares in Montreal, Canada headquartered Knight Therapeutics Inc. ended the session 1.04% lower at $9.49 with a total volume of 156,492 shares traded. Knight Therapeutics’ shares have gained 11.91% in the past one year. The stock is trading below its 50-day and 200-day moving averages. Furthermore, the stock’s 200-day moving average of $10.24 is greater than its 50-day moving average of $9.96. Shares of Knight Therapeutics, which engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally, are trading at PE ratio of 53.31. Register for free and access the latest research report on GUD.TO at:

http://protraderdaily.com/optin/?symbol=GUD

Acerus Pharmaceuticals Corp.

Mississauga, Canada headquartered Acerus Pharmaceuticals Corp.’s stock closed the day 4.55% higher at $0.12. The stock recorded a trading volume of 35,000 shares. Acerus Pharma’s shares have gained 20.00% in the previous one year. The Company’s shares are trading at their 50-day moving average of $0.12. Shares of the Company, which focuses on developing, manufacturing, marketing, and distributing pharmaceutical products for men’s urology and women’s hormone replacement therapy, and female sexual dysfunction, are trading at a PE ratio of 11.50. Get free access to your research report on ASP.TO at:

http://protraderdaily.com/optin/?symbol=ASP

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 470030

VANCOUVER, BC / ACCESSWIRE / July 31, 2017 / Canarc Resource Corp. (TSX: CCM, OTCQB: CRCUF, Frankfurt: CAN) is pleased to report that a recently completed surface rock-chip sampling and mapping program at its Fondaway Canyon property in Churchill County, Nevada has returned several high-grade gold values of over 5 gpt Au in multiple zones at surface.

Of the 42 surface rock-chip samples collected in June and July 2017, five samples assayed gold values of 10-24 gpt Au, eleven samples returned over 5 gpt Au and twenty-five samples essayed over 1 gpt Au.

Table 1 highlights the Fondaway Canyon 2017 rock-chip samples over 5 gpt Au

Sample

Type

Zone

gpt Au*

Width (m)

JM-FC9

Outcrop

Colorado

24.00

2.0

JM-FC37

Stockpile (UG)

Halfmoon

21.40

Composite

JM-FC42

Outcrop

Stibnite-Paperweight

19.80

2.0

JM-FC33

Outcrop

South Pit

15.75

0.5

JM-FC36

Stockpile (UG)

Halfmoon

11.45

Composite

JM-FC38

Stockpile (UG)

Halfmoon

9.62

Composite

JM-FC41

Outcrop

Stibnite-Paperweight

8.59

0.3

JM-FC40

Outcrop

Stibnite-Paperweight

7.91

2.0

JM-FC24

Outcrop

Halfmoon

5.87

3.0

JM-FC2

Outcrop

South Mouth

5.71

2.0

JM-FC13

Outcrop

Colorado

5.05

2.0

* All values in gpt; analysis by ALS Minerals; gold analyzed by 1 assay-ton fire assay and atomic absorption spectometry; gravimetric analysis for values exceeding 10 gpt Au; other elements by aqua-regia digestion and ICP-AES and ICP-MS techniques. Samples sorted by Au values.

Figure 1 illustrates the location and relative relationship of the numerous gold mineralized structures and zones at Fondaway Canyon.

In the Colorado zone, located at the northwest corner of the dilation zone where northeast-striking and east-west mineralized zones intersect, sample JM-FC9 returned very high-grade gold mineralization of 24.0 gpt Au over 2 meters. A sample from a steeply dipping shear vein in this area contained 5.0 gpt Au across 2 m (JM-FC13) while a sample from a nearby dike assayed 4.1 gpt Au (JM-FC8). Low-grade gold also occurs across broad areas of iron-stained, altered shale and siltstone, e.g., 0.95 gpt Au across 7 m (JM-FC10). Historic shallow drilling intersected significant gold mineralization within 125 meters of surface. Drill hole TF-114, intersected 7.4 gpt Au over 49 m including 17.6 gpt Au over 15 m. Drill hole TF-50 intersected 4.9 gpt over 50 m including 18.9 gpt over 7.6 m.

In the Stibnite-Paperweight zone, located at the northeast corner of the dilation zone, recent sampling has confirmed high-grade mineralization within steeply dipping and shallowly dipping shear veins. A chip sample across an east-west striking and steeply dipping shear vein returned 19.8 gpt over 2 meters (JM-FC42). The northeast-striking mineralization is a stock-work zone measuring at least 20 m wide at the surface exposure. The most recent sampling in this area returned 5.9 gpt over 3 m (JM-FC24) and 7.9 gpt over 2 m (JM-FC40) in steeply dipping structures and 8.6 gpt over 0.3 m (JM-FC41) in a shallowly-dipping structure. Historic drilling in this area has intersected mineralization exceeding 3 gpt Au down dip for about 350 m. Historic underground channel sampling of this zone by Tenneco in 1989 included 21.8 gpt over 1.5 m, 16.1 gpt over 3 m and 12.7 gpt over 3 m. Recently collected samples from surface stockpiles of this material returned 21.4 gpt Au (JM-FC37) and 11.4 gpt Au (JM-FC38). Historic drill hole 02FC-4 contained the deepest historic mineralization intersection with 4.2 gpt over 17 m.

In the South Pit zone, high-grade gold was also sampled at the structural intersection marking the southeast corner of the dilation zone. A 20-m wide northeast-trending mineralized structure intersects a 7-m wide east-west mineralized structure. 2017 chip sampling yielded 15.7 gpt Au over 0.5 m (JM-FC33). There has been limited historic drilling in this area, but historic drill hole (TF-219) in this vicinity contained 2.1 gpt Au over 15 m.

Parts of the South Mouth pit zone were mined by Tenneco Minerals in 1990 to depths of less than 30 meters. This area contains multiple veins across a width of at least 300 m and along an east-west strike for at least 700 m. No drilling has been done below 125 meters in this area. Recent sampling has confirmed strong gold mineralization along the east-west shear veins (3.3 gpt Au over 0.3 m; JM-FC3) as well as low-grade gold in altered shale (0.43 gpt over 1 m; JM-FC7).

Historic drilling in the vicinity of intersecting northeast and east-west trending structures at the Pack Rat area intersected 3.1 gpt Au over 18.3 m in hole TF-296 and 2.0 gpt Au over 38 m in hole P-25. Recent surface chip sampling yielded 3.1 gpt Au across a 0.5-m wide east-west striking shear vein (JM-FC19).

Canarc is encouraged by the positive results from the surface sampling and mapping program which confirm the presence of numerous high-grade mineralized zones at Fondaway Canyon and the potential for expansion of resources in these areas by drilling.

The positive results along with historic drilling and exploration information are being analyzed to help define high priority targets for a 2700-meter drilling campaign that will be undertaken in the fall of 2017.

Qualified Person:

Dr. Jacob Margolis is a qualified person, as defined by National Instrument 43-101, and has approved the technical information in this news release. Dr. Margolis is engaged as a consultant to Canarc Resource Corp.

“Catalin Kilofliski”

Catalin Kilofliski, CEO
CANARC RESOURCE CORP.

About Canarc Resource Corp. – Canarc is a growth-oriented, gold exploration and mining Company listed on the TSX (CCM) and the OTC-BB (CRCUF). The Company creates shareholder value by acquiring, exploring and developing pre-production stage gold mines or properties in the Americas.

For More Information – Please contact: 


Catalin Kilofliski, CEO
Tel: (604) 685-9700
 Fax: (604) 685-9744

Email: catalin@canarc.net 
Website: www.canarc.net

Cautionary Note Regarding Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the United States private securities litigation reform act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Statements contained in this news release that are not historic facts are forward-looking information that involves known and unknown risks and uncertainties. Forward-looking statements in this news release include, but are not limited to, statements with respect to the future performance of Canarc, and the Company’s plans and exploration programs for its mineral properties, including the timing of such plans and programs. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “has proven”, “expects” or “does not expect”, “is expected”, “potential”, “appears”, “budget”, “scheduled”, “estimates”, “forecasts”, “at least”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will be taken”, “occur” or “be achieved”.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and other factors include, among others, the Company’s ongoing due diligence review in relation to the Acquisition, risks related to the uncertainties inherent in the estimation of mineral resources; commodity prices; changes in general economic conditions; market sentiment; currency exchange rates; the Company’s ability to continue as a going concern; the Company’s ability to raise funds through equity financings; risks inherent in mineral exploration; risks related to operations in foreign countries; future prices of metals; failure of equipment or processes to operate as anticipated; accidents, labor disputes and other risks of the mining industry; delays in obtaining governmental approvals; government regulation of mining operations; environmental risks; title disputes or claims; limitations on insurance coverage and the timing and possible outcome of litigation. Although the Company has attempted to identify important factors that could affect the Company and may cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, do not place undue reliance on forward-looking statements. All statements are made as of the date of this news release and the Company is under no obligation to update or alter any forward-looking statements except as required under applicable securities laws.

SOURCE: Canarc Resource Corp.

ReleaseID: 470070

LONDON, UK / ACCESSWIRE / July 31, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select stocks with the Utilities – Independent Power Producers industry and that trades on the Toronto Exchanges. This Morning, our team has regrouped these stocks for study: Algonquin Power & Utilities, TransAlta, Alterra Power, and Atlantic Power. Register for these free reports at:

http://protraderdaily.com/register/

At the close of the Canadian markets on Friday, July 28, 2017, the Toronto Exchange Composite index ended the trading session at 15,128.65, 0.41% lower from its previous closing price.

The Utilities Index was also in the red, closing the day at 248.39, down 0.33%.

Pro-Trader Daily’s complimentary research reports on the following stocks are now available: Algonquin Power & Utilities Corporation (TSX: AQN), TransAlta Corporation (TSX: TA), Alterra Power Corporation (TSX: AXY), and Atlantic Power Corporation (TSX: ATP). Sign up now for your free membership and research reports at:

http://protraderdaily.com/register/

Algonquin Power & Utilities Corp.

Oakville, Canada headquartered Algonquin Power & Utilities Corp.’s stock edged 0.68% higher, to finish Friday’s session at $13.40 with a total volume of 630,494 shares traded. Over the last three months and the previous one year, Algonquin Power & Utilities’ shares have gained 3.32% and 10.11%, respectively. The Company’s shares are trading above its 200-day moving average. Algonquin Power & Utilities’ 50-day moving average of $13.55 is above its 200-day moving average of $12.81. Shares of the Company, which through its subsidiaries, engages in the generation, transmission, and distribution of utility assets in North America, are trading at a PE ratio of 68.72. See our research report on AQN.TO at:

http://protraderdaily.com/optin/?symbol=AQN

TransAlta Corp.

On Friday, shares in Calgary, Canada headquartered TransAlta Corp. recorded a trading volume of 331,557 shares. The stock ended the day 0.87% higher at $8.13. TransAlta’s stock has gained 15.98% in the last three months and 33.72% in the previous one year. The Company’s shares are trading above its 50-day and 200-day moving averages. The company stock’s 50-day moving average of $8.00 is above its 200-day moving average of $7.59. Shares of the Company, which operates as non-regulated electricity generation and energy marketing company in Canada, the US, and Western Australia, are trading at a PE ratio of 42.57. The complimentary research report on TA.TO at:

http://protraderdaily.com/optin/?symbol=TA

Alterra Power Corp.

On Friday, shares in Alterra Power Corp. ended the session 5.13% higher at $5.94 with a total volume of 19,128 shares traded. Alterra Power’s shares have gained 4.21% in the last one month and 25.85% in the previous three months. Shares of the Company, which through its subsidiary companies, operates, develops, explores and acquires renewable power projects, are trading above its 50-day and 200-day moving averages. Furthermore, the stock’s 50-day moving average of $5.74 is greater than its 200-day moving average of $5.21. Register for free and access the latest research report on AXY.TO at:

http://protraderdaily.com/optin/?symbol=AXY

Atlantic Power Corp.

Dedham, Massachusetts headquartered Atlantic Power Corp.’s stock closed the day 0.68% lower at $2.94. The stock recorded a trading volume of 73,118 shares, which was above its three months average volume of 50,230 shares. Shares of the Company, which owns and operates a fleet of power generation assets in the US and Canada, are trading below their 50-day and 200-day moving averages. Moreover, the stock’s 200-day moving average of $3.25 is greater than its 50-day moving average of $3.10. Get free access to your research report on ATP.TO at:

http://protraderdaily.com/optin/?symbol=ATP

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 470029

SAN ANTONIO, TX / ACCESSWIRE / July 31, 2017 / MIRAGE ENERGY CORPORATION (OTC PINK: MRGE) announces, through its wholly owned subsidiary, WPF Mexico Pipelines, S. de R. L. de C. V., the completion of the engineering designs for its 36-inch natural gas Arguelles Pipeline.

Project Consulting Services (PCS), Mirage’s project management and engineering firm, has completed the engineered designs and schematics for the company’s 36-inch natural gas pipeline in the country of Mexico. The Arguelles pipeline will connect to the company’s storage field in Mexico and travel West making interconnects to the major trunk lines in Mexico. Mirage is working hand-in-hand with CENAGAS, the government agency that controls the national pipeline system of Mexico, to pinpoint exact locations for its pipeline tie-ins points on the national system. This 36-inch pipeline will be bi-directional allowing gas to be injected into the company’s storage field from the Mexican national pipeline system and also extracted from the storage field and delivered to the various customers in Mexico.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. These statements relate to future events or our future financial performance. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management’s best judgment as to what may occur in the future. However, forward-looking statements are subject to risk, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected.

SOURCE: Mirage Energy Corporation

ReleaseID: 470035

WEST LAFAYETTE, IN / ACCESSWIRE / July 31, 2017 / Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”), a recognized global leader in the development of instrumentation for automated blood sampling in animal models, today announced that it has entered into a reseller agreement with LABEX of MA (“LABEX”) for refurbished BASi Culex® Automated Blood Sampling Systems.

BASi Culex Automated Blood Sampling Systems deliver programmable, continuous, automated blood micro sampling that provides a full pharmacokinetic curve from a single, fully conscious, freely-moving animal. The system allows for the simultaneous collection of multiple data streams such as blood, bile, metabolites, dialysates and more. LABEX is a leading source of reconditioned and used animal caging and vivarium equipment.

“We couldn’t be more pleased to be partnering with LABEX as a reseller of our refurbished Culex systems given their industry experience, a broad network of loyal customers, and exceptional client care,” said Alan Loch, Director of Business Development for BASi. “Our Culex systems perfectly complement LABEX’s already incomparable array of high-quality, reconditioned and used vivarium equipment.”

Ed Russo, President of LABEX of MA said, “Everyone here at LABEX is excited about our recent partnership with BASi. We are hopeful it will open many doors for us while we are able to help our customers purchase top-notch blood sampling systems.”

About LABEX of MA

LABEX of MA brings together a unique combination of industry experience and unmatched inventory for providing the best choice for reconditioned vivarium equipment. The Company’s tremendous industry experience and broad network makes them uniquely qualified to understand the needs and requirements of the university, research, pharmaceutical and biotechnology clients. Visit www.labexofma.com for more about LABEX of MA.

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world’s leading drug development companies and medical research organizations. The Company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more information about BASi.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company’s filings with the Securities and Exchange Commission.

Company Contact:

Jill Blumhoff
Chief Financial Officer & Vice President of Finance
Phone: 765.497.8381
jblumhoff@BASinc.com

SOURCE: Bioanalytical Systems, Inc.

ReleaseID: 469968

NEW YORK, NY / ACCESSWIRE / July 31, 2017 / Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) will be discussing their earnings results in their Q2 Earnings Call to be held July 31, 2017 at 8:30 AM Eastern Time.

To listen to the event live – visit https://www.investornetwork.com/company/24401.

Replay Information

The replay will be available online at https://www.investornetwork.com/company/24401.

About Investor Network

Investor Network (IN) is a new financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 470075

NEW YORK, NY / ACCESSWIRE / July 31, 2017 / Affiliated Managers Group, Inc. (NYSE: AMG) will be discussing their earnings results in their Q2 Earnings Call to be held July 31, 2017 at 8:30 AM Eastern Time.

To listen to the event live – visit https://www.investornetwork.com/company/2704.

Replay Information

The replay will be available online at https://www.investornetwork.com/company/2704.

About Investor Network

Investor Network (IN) is a new financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 470076

NEW YORK, NY / ACCESSWIRE / July 31, 2017 / Sanofi (NYSE: SNY) will be discussing their earnings results in their Q2 Earnings Call to be held July 31, 2017 at 8:30 AM Eastern Time.

To listen to the event live – visit https://www.investornetwork.com/company/357.

Replay Information

The replay will be available online at https://www.investornetwork.com/company/357.

About Investor Network

Investor Network (IN) is a new financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 470074

Research Desk Line-up: C. R. Bard Post Earnings Coverage

LONDON, UK / ACCESSWIRE / July 31, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Haemonetics Corp. (NYSE: HAE), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=HAE. The Company announced on July 28, 2017, that it has received FDA 510(k) clearance for its NexSys PCS plasmapheresis system. Haemonetics is a global health care Company which delivers a suite of hemotology products and solutions for the customers. The NexSys PCS includes bi-directional connectivity to Haemonetics’ donor management system, NexLynk DMS, and builds on Haemonetics’ industry leading position with a user-centric research-based design. For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Medical Instruments & Supplies industry. Pro-TD has currently selected C. R. Bard, Inc. (NYSE: BCR) for due-diligence and potential coverage as the Company reported on its financial results for Q2 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on C. R. Bard when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on HAE; also brushing on BCR. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=HAE

http://protraderdaily.com/optin/?symbol=BCR

The Announcement

The Company views this announcement as a step to expand its product range in its domestic market and improve quality and compliance in plasma collection centers. The open architecture of NexSys PCS facilitates bi-directional connectivity to donor management systems to help with the automated collection procedure programming and automated end of procedure documentation. The simple guided operation, intuitive touch screen, and on-screen troubleshooting assistance on this machine enhance the plasma center efficiencies resulting in reduced total time for donors in the center and greater collection capacity per plasma center.

NextSys PCS and NextLynk DMS were previously known as PCS 300 and NextGen DMS. On December 08, 2016, Haemonetics released an extensive upgrade to NextGen DMS (Donor Management System), an innovative software suite, where the core feature upgrades included reducing the cost per liter of plasma collected, enhanced quality and regulatory compliance, where the Company leveraged data to analyze and improve plasma center operations. The release of NextGen DMS 4 enabled the automated donor address verification, paperless intake, and annual medical assessment, where the device has extended capabilities of the donor floor mobile application to streamline phlebotomy documentation.

PCS, the Plasma Collection System

PCS is a premier plasma collection system with self-loading pumps, auto-priming, comprehensive messaging, advanced optical sensors, minimal alarms, and easy-to-read display. The system includes multiple safety features, including redundant air detectors, a donor line pressure monitor, low anticoagulant ratios, a fluid sensor, and an enclosed centrifuge. The system is also available for use with EXPRESS software, an intelligent algorithm that contributes to a reduction in overall donation time.

Company Growth Prospects

Haemonetics, being a health care-oriented firm, has aimed to achieve equilibrium for enhanced productivity across the Company’s corporate structure. It formed a Scientific Advisory Council on June 22, 2017, as a part of its broader innovation agenda, advancing its commitment to scientific and clinical excellence. The SAC, composed of 15 leading physician-scientists, would advise Haemonetics’s management and Board of Directors on key clinical and scientific issues. The SAC will also, as appropriate, deliver an opinion on strategic issues impacting product and clinical matters.

Haemonetics released its full-year FY17 results on May 08, 2017, where it reported a net operating loss of $19.4 million against $43.9 million loss in full-year FY16. The Company reported its FY18 guidance where in the plasma sector, it expects a growth of 3%-5% YOY; in the Hospital sector, a growth of 7%-10%; and a 7%-10% decline in the Blood Center sector. The Company also included the anticipated investments of $70 million to $90 million in FY18 guidance.

Last Close Stock Review

On Friday, July 28, 2017, the stock closed the trading session at $42.00, jumping 6.36% from its previous closing price of $39.49. A total volume of 988.12 thousand shares have exchanged hands, which was higher than the 3-month average volume of 305.91 thousand shares. Haemonetics’ stock price soared 0.29% in the last three months, 5.50% in the past six months, and 40.75% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have gained 4.48%. At Friday’s closing price, the stock’s net capitalization stands at $2.07 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 470060

Research Desk Line-up: IRadimed Post Earnings Coverage

LONDON, UK / ACCESSWIRE / July 31, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Cesca Therapeutics Inc. (NASDAQ: KOOL) (“Cesca”), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=KOOL. The Company, which is a market leader in automated cell processing, announced on July 28, 2017, that the US Patent and Trademark Office has awarded a new US Patent (the ‘394 patent’), entitled Cell Separation Devices, Systems, and Methods to SynGen, Inc., whose cell processing assets were acquired by ThermoGenesis Corp. on July 10, 2017. For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Medical Appliances & Equipment industry. Pro-TD has currently selected IRadimed Corporation (NASDAQ: IRMD) for due-diligence and potential coverage as the Company announced on July 28, 2017, its financial results for Q2 2017 which ended on June 30, 2017. Tune into our site to register for a free membership, and be among the early birds that get our report on IRadimed when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on KOOL; also brushing on IRMD. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=KOOL

http://protraderdaily.com/optin/?symbol=IRMD

ThermoGenesis Corp., a leader in developing and manufacturing automated blood and bone marrow processing systems, and companion disposable products, merged with TotipotentRX to form ThermoGenesis, changing its corporate name to Cesca Therapeutics Inc., on February 13, 2014.

‘394 Patent’

Automated Cellular Separation and BACS Processes – Cesca’s ‘394 patent’ covers a device and methodology for integrating automated cellular separation and buoyancy-activated cell sorting (BACS) processes. BACS employs microscopic bubbles to isolate a specific cell type from a complex mixture of cells, such as blood. The patent also permits the automated isolation of cells with low-density surface antigens, which was previously a major cellular manufacturing challenge.

Platform for Development of CAR-T and CAR-NK Therapeutics – The patent relates to the automated isolation of rare, therapeutically critical target cells from blood, bone marrow, leukapheresis product, and other cell sources while maintaining the viability of the cells under asceptic conditions. This advanced technology is part of Cesca’s proprietary CAR-TXpress™ platform, an automated solution that isolates target cells using patented BACS technology. The CAR-TXpress™ system provides a comprehensive and commercially viable, automated cellular manufacturing and control (CMC) solution for the development of CAR-T and CAR-NK therapeutics.

Strengthens the Intellectual Property Position

Commenting on the issuance of the patent, Chris Xu, Cesca’s Chief Executive Officer stated:

“This new patent issuance significantly strengthens the intellectual property position surrounding our proprietary automation technology which is core to our best-in-class ThermoGenesis portfolio of cell processing systems. Traditional cell processing methodologies, including those currently being implemented and used by leading CAR-T developers, are manual and time-consuming, presenting significant challenges to the future large-scale commercial feasibility of these revolutionary therapies.”

He further added:

“Cesca’s patented, automated cell processing systems provide greater cell yields and higher consistency in a fraction of the time, making them ideally suited to meet industry needs. The ability to leverage our technology to commercialize the BACS process is a milestone achievement for our company.”

About Cesca Therapeutics Inc.

Founded in 1986, Cesca is a leading regenerative medicine company that develops, commercializes, and markets a range of automated technologies for cell-based therapeutics. The Company’s device division, ThermoGenesis Corp., provides a full suite of solutions for automated clinical bio-banking, point-of-care applications, and automation for immuno-oncology. Cesca is an affiliate of the BoyaLife Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine. The Company is headquartered in Rancho Cordova, California.

Last Close Stock Review

On Friday, July 28, 2017, the stock closed the trading session at $3.85, surging 11.92% from its previous closing price of $3.44. A total volume of 3.19 million shares have exchanged hands, which was higher than the 3-month average volume of 37.82 thousand shares. Cesca Therapeutics’ stock price surged 23.00% in the last one month, 24.60% in the past three months, and 30.07% in the previous six months. Furthermore, since the start of the year, shares of the Company have rallied 11.59%. The stock currently has a market cap of $34.11 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 470054